Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Adhera Therapeutics Inc (ATRX)

Adhera Therapeutics Inc (ATRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 1
  • Shares Outstanding, K 11,627
  • Annual Sales, $ 0 K
  • Annual Income, $ -2,110 K
  • 60-Month Beta 0.15
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade ATRX with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.15
  • Most Recent Earnings $-0.83 on 11/20/23
  • Next Earnings Date 09/23/24 [--]
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0001 unch
on 09/13/24
0.0024 -95.83%
on 08/30/24
-0.0079 (-98.75%)
since 07/24/24
3-Month
0.0001 unch
on 09/13/24
0.0170 -99.41%
on 06/28/24
-0.0042 (-97.67%)
since 06/11/24
52-Week
0.0001 unch
on 09/13/24
0.0475 -99.79%
on 11/30/23
-0.0199 (-99.50%)
since 09/13/23

Most Recent Stories

More News
Adhera Therapeutics Signs Letter of Intent to Acquire CD71-Targeted Cancer Therapy Paclitaxel Gallium Transferrin

Baton Rouge, LA, July 19, 2022 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCQB: ATRX) ("Adhera" or the "Company"), a clinical stage...

OTC.VN : 0.305 (unch)
ATRX : 0.0001 (unch)
Adhera Therapeutics Appoints Trond K. Waerness as Chairman of the Board, Company Focuses on Uplist to NASDAQ

Baton Rouge, LA, May 19, 2022 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCQB: ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical...

OTC.VN : 0.305 (unch)
ATRX : 0.0001 (unch)
Adhera Therapeutics Names Preeminent Diabetes Pioneer Dr. Jean Buteau to Scientific Advisory Board

Baton Rouge, LA, March 21, 2022 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCPK: ATRX) ("Adhera" or the "Company"), a clinical stage...

OTC.VN : 0.305 (unch)
ATRX : 0.0001 (unch)
Adhera Therapeutics Announces Uplisting to OTCQB Venture Marketplace

Baton Rouge, LA, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCPK: ATRX) ("Adhera" or the "Company"), a clinical stage...

OTC.VN : 0.305 (unch)
ATRX : 0.0001 (unch)
Adhera Therapeutics Receives Notice of Allowance for New Canadian Patent Covering MLR-1019 for Dyskinesia and Related Disorders

Baton Rouge, LA, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCPK: ATRX) ("Adhera" or the "Company"), a clinical stage...

OTC.VN : 0.305 (unch)
ATRX : 0.0001 (unch)
Adhera Therapeutics Announces Appointment of Dr. Zahed Subhan to Board of Directors

Baton Rouge, LA, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCPK: ATRX) ("Adhera" or the "Company"), a clinical stage...

OTC.VN : 0.305 (unch)
ATRX : 0.0001 (unch)
Adhera Therapeutics Expands Relationship with Melior Pharmaceuticals I, Adds NASH and Pulmonary Inflammation to Portfolio of Target Indications

Adhera has an exclusive license agreement with Melior Pharmaceuticals I, pursuant to which Adhera is advancing MLR-1023 (tolimidone) into Phase 2 trials...

OTC.VN : 0.305 (unch)
ATRX : 0.0001 (unch)
Adhera Therapeutics Provides Insight on Corporate Strategy, Development of Parkinson’s Disease and Type 1 Diabetes Drugs

Baton Rouge, LA, Sept. 13, 2021 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCPK: ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, today provides shareholders an update...

ATRX : 0.0001 (unch)
Adhera Therapeutics Appoints Dr. Andrew Reaume to Board of Directors

Baton Rouge, LA, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCPK: ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, is pleased to announce the appointment...

ATRX : 0.0001 (unch)
Adhera Therapeutics Signs Exclusive License Agreement with Melior Pharmaceuticals I for New Type 1 Diabetes Drug Candidate

Baton Rouge, LA, Aug. 24, 2021 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCPK: ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, is pleased to announce that the Company...

ATRX : 0.0001 (unch)

Business Summary

Adhera Therapeutics Inc. is a bio-technology company. It researches and develops therapies for the treatment of inflammatory diseases, hyper-tension and cancer. The company's product pipeline consists of PRESTALIA(R) and DyrctAxess which are in clinical stage. Adhera Therapeutics Inc., formerly known...

See More

Key Turning Points

3rd Resistance Point 0.0001
2nd Resistance Point 0.0001
1st Resistance Point 0.0001
Last Price 0.0001
1st Support Level 0.0001
2nd Support Level 0.0001
3rd Support Level 0.0001

See More

52-Week High 0.0475
Fibonacci 61.8% 0.0294
Fibonacci 50% 0.0238
Fibonacci 38.2% 0.0182
Last Price 0.0001
52-Week Low 0.0001

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar